Ophthalmology Consultants, Ltd. — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$22,653	4
2021	Research	$151,374	20
2020	Research	$29,584	11
2019	Research	$42,664	19

Breakdown

Who paid Research payments · program years 2019–2022

Bausch Health US, LLC $126,641 12 payments
Glaukos Corporation $78,393 33 payments
Bausch & Lomb Americas Inc. $20,866 3 payments
Ocular Therapeutix, Inc. $20,375 6 payments

Studies the money was for Research payments · program years 2019–2022

A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (Mojave Study) $84,650 9 payments
A Study to Document the Safety and Effectiveness of A New Cohesive Ovd When Compared to A Control Ovd $62,857 6 payments
A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Post-Approval Study of the Glaukos iStent Trabecular Micro-Bypass Stent System in Conjunction with Cataract Surgery $57,770 21 payments
A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery $20,623 12 payments
A Randomized, Double-Masked, Vehicle-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease (DED) $18,588 5 payments
A Randomized, Double-Masked, Vehicle-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease (DED) $1,788 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.